2014 Bethesda系统实施与人乳头瘤病毒原发筛查:CAP PAP教育计划参与实验室实践调查
该研究通过2016和2017年随CAP PAP教育计划邮寄的问卷,调查宫颈细胞病理学实践因2014 Bethesda系统更新和筛查技术而发生的变化。结果显示多数实验室已采纳或计划采纳2014 Bethesda更新,但部分实践如LSIL-H术语使用和5000细胞阈值仍存在差异;2017年多数实验室未提供独立HPV原发筛查,Roche Cobas是最常用平台。
要点
- 2016年多数实验室已采纳或计划采纳2014 Bethesda系统更新。
- 51.3%实验室对不确定病例使用LSIL-H术语,44.9%采用5000细胞阈值。
- 2017年59.4%实验室未提供独立HPV原发筛查,Roche Cobas最常见。
核心结论
- 问卷调查提供了宫颈细胞学筛查现状数据,包括2014 Bethesda系统更新相关变化和HPV原发筛查技术的采纳情况。
研究设计与样本
- 2016和2017年随CAP PAP教育计划邮寄问卷进行调查。
主要发现
- 2016年多数实验室已采纳或计划采纳2014 Bethesda系统更新。
- 53%(365/689)实验室使用45岁 cutoff 报告良性外观子宫内膜细胞。
- 51.3%(354/690)实验室对不确定特征病例使用LSIL-H术语。
- 44.9%(298/664)实验室对子宫切除后和治疗后标本采用5000细胞 cutoff 作为最小鳞状细胞量。
- 2013至2016年宫颈细胞学指标报告率变化很小,ASC/SIL中位比值ThinPrep为1.9,SurePath为1.8。
关键数值与推荐
- 53%(365/689)实验室使用45岁 cutoff 报告良性外观子宫内膜细胞。
- 51.3%(354/690)实验室使用LSIL-H术语。
- 44.9%(298/664)实验室采用5000细胞 cutoff。
- ASC/SIL中位比值ThinPrep为1.9,SurePath为1.8。
- 59.4%(389/655)实验室2017年未提供独立HPV原发筛查。
临床怎么用
- 实验室可参考调查数据了解2014 Bethesda系统更新和HPV原发筛查的采纳现状。
- Roche Cobas是HPV原发筛查最常用平台。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT.—: Cervical cancer screening laboratory practices may evolve with new terminology and technologies. OBJECTIVE.—: To investigate changes in cervical cytopathology practice resulting from the 2014 Bethesda System updates and screening technologies. DESIGN.—: Questionnaires accompanied 2016 and 2017 mailings of the College of American Pathologists PAP Education program. RESULTS.—: In 2016, most laboratories surveyed had adopted or were planning to adopt 2014 Bethesda System updates, and the majority (53%; 365 of 689) used an age cutoff of 45 for reporting benign-appearing endometrial cells. However, 51.3% (354 of 690) of laboratories used the term low-grade squamous intraepithelial lesion, cannot exclude high-grade squamous intraepithelial lesion, for cases with indeterminate features, and 44.9% (298 of 664) of laboratories used a 5000-cell cutoff for minimum squamous cellularity for posthysterectomy and posttherapy specimens. Reporting rates for cervical cytology metrics changed very little from 2013 to 2016, and the median ratio of atypical squamous cells to squamous intraepithelial lesion cases was 1.9 for ThinPrep and 1.8 for SurePath preparations. Most laboratories (59.4%; 389 of 655) did not offer stand-alone primary human papillomavirus (HPV) testing in 2017, and primary HPV testing accounted for a low proportion of HPV testing volumes. The Roche Cobas method was the most common platform for HPV primary screening. CONCLUSIONS.—: These questionnaire surveys provide data about the current status of cervical cytology screening, including changes related to the 2014 Bethesda System updates and the adoption of HPV primary screening techniques.
引用
- Davey DD, Souers RJ, Goodrich K, et al. Bethesda 2014 Implementation and Human Papillomavirus Primary Screening: Practices of Laboratories Participating in the College of American Pathologists PAP Education Program. Arch Pathol Lab Med. 2019. PMID: 31021657. doi:10.5858/arpa.2018-0603-CP
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。